Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8

Bergman, Ira; Barmada, Mamdouha A.; Heller, Glenn; Griffin, Judith A.; Cheung, Nai‐Kong V.

doi:10.1002/(sici)1097-0215(19990812)82:4<538::aid-ijc12>3.0.co;2-7

Cited by 12 publications

(2 citation statements)

References 33 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If such analysis is positive, then CNS prophylactic strategies clearly are considerations, especially at the time of minimal residual disease. In addition, novel, tumor‐selective therapy, when applied to the craniospinal axis, may have potential in inhibiting leptomeningeal tumor growth 38, 39…”

Section: Discussionmentioning

confidence: 99%

Neuroblastoma metastatic to the central nervous system

Krämer

Kushner

Heller

et al. 2001

Cancer

Self Cite

128

View full text Add to dashboard Cite

BACKGROUND The central nervous system (CNS) can be a sanctuary site for cancer cells, because the blood‐brain barrier impedes penetration of most chemotherapeutic agents. The authors hypothesized that, with improved survival from childhood metastatic neuroblastoma (NB), the incidence of CNS (intraparenchymal and leptomeningeal) spread may increase. They undertook this study to assess the frequency of CNS NB, to analyze risk factors and treatment options, and to review the literature. METHODS The authors retrospectively analyzed all patients with metastatic NB who were treated on protocols N4, N5, N6, and N7 from 1980 to 1999 at Memorial Sloan‐Kettering Cancer Center (MSKCC), during which time there was an increase in the overall survival rate. RESULTS Two hundred fifty‐one patients with Stage 4 NB (Group 251) were studied, of which 127 (Group 127) were newly diagnosed patients who were treated initially at MSKCC. None had CNS NB at the time of diagnosis. Eleven patients developed documented CNS disease; 8 of these 11 recurrences were isolated in the CNS. For Group 127, the overall incidence rate of CNS NB was 6.3%, with an increase in incidence from N4‐N5 to N6‐N7 of from 1.7% to 11.7%. Seven patients had isolated CNS disease recurrences. Only lumbar punctures (LP) performed near the time of diagnosis in patients with known bone marrow involvement were associated with subsequent development of CNS disease. For the entire group of 251 patients, lumbar puncture at the time of diagnosis and elevated serum lactic dehydrogenase levels were prognostic. Among the larger series reported in the literature, CNS involvement from metastatic lesions was rare at the time of diagnosis and remained an uncommon complication. CONCLUSIONS The incidence of CNS NB may be increasing. Because it is the sole site of disease recurrence in 64% of patients, the CNS may represent a sanctuary site for NB. CNS NB is associated with diagnostic lumbar punctures in patients with known bone marrow disease, raising the possibility that circulating or epidural microscopic tumor cells may seed the craniospinal axis. Cancer 2001;91:1510–9. © 2001 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuroblastoma metastatic to the central nervous system

Krämer

Kushner

Heller

et al. 2001

Cancer

Self Cite

128

View full text Add to dashboard Cite

show abstract

“…There has been increasing interest in the use of the intracerebroventricular (icv) route for administration of antibodies for treatment of malignancies in the central nervous system (CNS) (Colapinto et al, 1990; Liebert et al, 1990; Laske et al, 1997; Bergman et al, 1999; Gonzalez et al, 2000). Intracerebroventricular antibodies have also been utilized for investigation of certain aspects of CNS physiology and structure.…”

mentioning

confidence: 99%

Distribution of intraventricularly administered antiamyloid‐beta peptide (Aβ) antibody in the mouse brain

Chauhan

Siegel

Lichtor

2001

J of Neuroscience Research

View full text Add to dashboard Cite

There is considerable interest in utilizing the intracerebroventricular (icv) route of administration of antibodies in the brain for various studies and for the therapy of malignancies, but very little is known about the anatomic extent of distribution of the antibody in brain after injection into the third ventricle. To explore the potential for icv administration of antiamyloid-beta peptide (Abeta) in reducing Abeta toxicity in brain in Alzheimer's disease, we first mapped the time course and path of transit of horseradish peroxidase (HRP)-labeled antibody. The results show that, after a single injection into the mouse third venticle, the HRP-labeled antibody is localized within the microvasculature, first that of the corticohippocampal region close to the site of injection at 3 hr. By 24 hr, the antibody is distributed throughout the hippocampus and frontoparietal cortex close to the injection site, as well as in the deep and outer cerebral cortex and cerebellar cortex remote from the injection site. The injected antibody is almost entirely removed by 4 days. Therefore, the antibody had diffused throughout all the brain by 24 hr, showing the feasibility of small quantities of anti-Abeta antibody infused into the third ventricle to reach extracellular epitopes throughout the brain parenchyma rapidly.

show abstract

Improving the Outcome of Patients with Leptomeningeal Cancer: New Clinical Trials and Experimental Therapies

Jaeckle

Cancer Treatment and Research

View full text Add to dashboard Cite

Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8

Cited by 12 publications

References 33 publications

Neuroblastoma metastatic to the central nervous system

Neuroblastoma metastatic to the central nervous system

Distribution of intraventricularly administered antiamyloid‐beta peptide (Aβ) antibody in the mouse brain

Improving the Outcome of Patients with Leptomeningeal Cancer: New Clinical Trials and Experimental Therapies

Contact Info

Product

Resources

About